RARE (Ultragenyx Pharmaceutical) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


RARE Ultragenyx Pharmaceutical Inc RARE
65 GF Score
Price $29.11
GF Value $46.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ultragenyx Pharmaceutical's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

RARE vs ELVN, KOD, CLDX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultragenyx Pharmaceutical Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Margin of Safety % (DCF Earnings Based) falls into.


RARE
65GF Score
Ultragenyx Pharmaceutical Inc RARE
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ultragenyx Pharmaceutical (RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $29.11 is trading 38.1% below its estimated GF Value™ of $46.99. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for RARE:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $46.99 vs. price of $29.11 (38.1% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
65GF Score

Get the complete analysis for RARE

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.11
Price
$46.99
GF Value